VA-INTELSAT
23.5.2024 15:31:29 CEST | Business Wire | Press release
Intelsat, operator of one of the world’s largest integrated satellite and terrestrial networks and leading provider of inflight connectivity (IFC), will deliver years of additional reliable broadband, video distribution and mobile satellite service to customers across three continents thanks to the success of Northrop Grumman’s innovative Mission Extension Vehicle (MEV) that will ultimately provide an expected additional nine years of life to the Intelsat 10-02 (IS-10-02) geosynchronous satellite.
Geosynchronous Earth orbit (GEO) satellites have an average lifespan of about 15-20 years before they start running low on fuel. Intelsat in 2020 became the first satellite operator to commit to deploying two of Northrop Grumman’s MEVs to extend the life of an otherwise healthy satellite. Both MEVs have been successful at their mission and have allowed IS-10-02 and Intelsat 901 (IS-901) to provide five years of service beyond the expected lifespan of the satellite. Under amendments to the original agreements with Northrop Grumman’s SpaceLogistics LLC, both MEVs will stay in space serving Intelsat satellites for several more years, allowing them to operate longer.
- At the end of the current servicing period, MEV-1 will release the IS-901 satellite into the GEO graveyard and then provide service for another Intelsat satellite.
- MEV-2 will remain docked to Intelsat’s current vehicle, IS-10-02, providing life-extension for several years – nearly doubling service from the original contract. The IS-10-02 satellite was manufactured by Airbus Defense & Space, was launched in June 2004 and entered service in August 2004. Capacity on the satellite is shared with Telenor Satellite. Today, MEV-2 is helping to extend the life of IS-10-02, so the satellite can continue providing high-quality media distribution and broadband services to our customers across Europe, the Middle East, Africa and South America. IS-10-02 is a key satellite in the Intelsat-Telenor Satellite video neighborhood, distributing more than 900 channels to nearly 18 million television households across Europe.
“As the largest satellite operator in geosynchronous orbit, Intelsat has always been committed to continuous reliable service, as well as leadership in furthering sustainable space operations,” said Jean-Luc Froeliger, SVP Space Systems at Intelsat. “Intelsat continues to pursue first-of-their-kind innovations to extend the life of its satellites in orbit, while also bringing the industry together to foster information sharing and collaboration across a challenging regulatory environment to achieve sustainable stewardship of the resource of space.”
“This extension is excellent news for our many clients across Europe and the Middle East who are served by THOR 10-02,” said Morten Tengs, CEO of Telenor Satellite. “We pride ourselves on the resilience of our service and, by extending the life of the satellite, we can ensure continuity and hassle-free operations for a number of years.”
MEV Background
In 2020, MEV-1 successfully docked with the IS-901 satellite, a high-performing satellite that was running low on fuel. That marked the first time that two commercial spacecraft docked and began mission-extension service in GEO. The in-space maneuver pointed IS-901 to targeted antennas on Earth and extended its life for another five years of its lifespan.
In 2021, the feat was repeated with a second MEV-2 docking with the IS-10-02 satellite. Unlike the first docking, which was performed in a graveyard orbit a few hundred kilometers above active satellites, this time the MEV-2 docked with IS-10-02 in its original orbital slot and avoided any interruption of services to customers, resulting in the first-ever in-orbit servicing of a live commercial satellite in GEO.
About Intelsat
Intelsat’s global team of professionals is focused on providing seamless and secure, satellite-based communications to government, NGO and commercial customers through the company’s next-generation worldwide network and managed services. Bridging the digital divide by operating one of the world’s largest and most advanced satellite fleet and connectivity infrastructures, Intelsat enables people and their tools to speak over oceans, see across continents and listen through the skies to communicate, cooperate and coexist. Since its founding six decades ago, the company has been synonymous with satellite-industry “firsts” in service to its customers and the planet. Leaning on a legacy of innovation and focusing on addressing a new generation of challenges Intelsat team members now have their sights on the “next firsts” in space as they disrupt the field and lead in the digital transformation of the industry.
Follow Us on Social Media:
X | LinkedIn | Instagram | YouTube
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523619448/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
